The Medical Letter on Drugs and Therapeutics
Eslicarbazepine Acetate (Aptiom) for Epilepsy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Eslicarbazepine acetate (Aptiom – Sunovion) has been approved by the FDA for adjunctive treatment of partial-onset seizures in adults. New drugs for epilepsy are often approved by the FDA initially only as adjunctive treatment for partial seizures.1 Eslicarbazepine acetate is a prodrug of eslicarbazepine, which is the S-isomer of the active metabolite of oxcarbazepine. Oxcarbazepine itself is similar to carbamazepine. Both oxcarbazepine and carbamazepine are available generically.

MECHANISM OF ACTION — As with oxcarbazepine and carbamazepine, the antiepileptic activity of eslicarbazepine is believed to be due to inhibition of voltage-gated sodium channels, which reduces membrane excitability.2

CLINICAL STUDIES — Approval of eslicarbazepine acetate was based on the results of 3 randomized, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Eslicarbazepine Acetate (Aptiom) for Epilepsy
Article code: 1443b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian